WeTranslate

Decide which pillar fits your asset

WeTranslate's four pillars are not interchangeable, and the right entry point depends on where your asset is in its life.

• Have a peptide or monoclonal antibody you want partnered: the Strategic Licensing pillar, for in-licensing and out-licensing.
• Have a laboratory breakthrough that needs to reach manufacturing: the Tech-Transfer and Scale-Up pillar.
• Have a mature pharmaceutical asset and are raising capital: the Strategic Consulting pillar, which pairs technology due diligence with capital-raising advisory.
• Working on AI in drug discovery: the AI and Digital Health pillar.

How engagement works

There is no cohort to apply to and no intake window. You reach the firm directly to discuss your asset and which pillar fits, and the work proceeds as an advisory engagement rather than a selection round.

What to have ready

Because the firm works on specific life-science assets, come with a clear description of the asset itself, its stage, and what you want from the engagement, whether that is a licensing partner, a path to manufacturing scale-up, due diligence for a raise, or AI support for discovery.

WeTranslate is a boutique advisory firm that works on the commercialisation of life-sciences innovation, with a focus on peptides, monoclonal antibodies and mature pharmaceutical assets. It positions itself as an intellectual incubator rather than a cohort-based programme, and it engages companies through its four pillars of strategic support, described as a model to accelerate the journey from molecule to market. It operates online at wetranslate.science.

What they support

WeTranslate is built for innovation-driven life-science companies rather than general early-stage startups. The firm's own description is of a service that helps innovators with assets such as peptides and monoclonal antibodies find global partners, move laboratory work toward manufacturing, raise capital against mature assets, and bring AI into drug discovery. There is no sector-agnostic incubation here: the firm's language throughout is deep-science and pharmaceutical.

There is no cohort, no batch and no application intake described anywhere. Each pillar is an advisory engagement a company enters by contacting the firm, in some cases beginning with an introductory session, rather than by applying to a dated call.

Programmes

WeTranslate organises its work into four advisory pillars.

Strategic Licensing covers both in-licensing and out-licensing. The firm describes end-to-end licensing support for peptides and monoclonal antibodies, connecting innovators with global partners for technology transfer and commercialisation.

Tech-Transfer and Scale-Up is a process-development pillar. The firm describes hands-on support from early-stage development through manufacturing scale-up, aimed at translating laboratory breakthroughs into commercial-ready products.

Strategic Consulting covers technology due diligence and advisory for capital raising, focused on mature pharmaceutical assets that are ready for global markets.

AI and Digital Health covers the use of generative AI for accelerated drug discovery.

How to apply

There is no application form or cohort intake. A company that wants to work with WeTranslate contacts the firm directly, through its enquiry route, to discuss fit; the licensing and advisory pillars begin with that conversation rather than a selection round. Because the engagement is advisory and partner-led, who is a fit depends on the asset a company brings and the pillar it needs.